In an unprecedented move, the Food and Drug Administration rescinded a recent decision that an Alkermes (ALKS) drug being developed for treating depression would not be reviewed. And the sudden reversal is raising questions about the extent to which the agency is willing to become more flexible about drug approvals in an overheated political climate focused on access to medicines.

Here’s the backstory: On April 2, the company unexpectedly disclosed that the FDA issued a so-called refuse-to-file letter, which meant the marketing application for its drug would not be reviewed. Why? There was “insufficient evidence of overall effectiveness” in treatment-resistant depression, and the agency wanted additional “well-controlled clinical trials.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy